APO Research
Talk to an analyst

APO RESEARCH · REPORT

Lenalidomide

Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma (MM) and myelodysplastic syndromes (MDS). For MM it is used after at least one other treatment and generally together with dexamethasone.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma (MM) and myelodysplastic syndromes (MDS). For MM it is used after at least one other treatment and generally together with dexamethasone.

Selected research

Market Outlook & Growth Opportunities

Global Lenalidomide Market Outlook and Growth Opportunities 2026

21 December 2025192 pages

Choose your research edition.

Industry ResearchLenalidomide Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Lenalidomide Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Lenalidomide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032171 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lenalidomide Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Lenalidomide Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma (MM) and myelodysplastic syndromes (MDS). For MM it is used after at least one other treatment and generally together with dexamethasone.

In China, Lenalidomide key players include Celgene, SL Pharma.

In terms of product, 25 mg Capsules is the largest segment, with a share over 40%. And in terms of application, the largest application is Multiple myeloma (MM), followed by Myelodysplastic syndromes (MDS).

Read the full market overview

This report provides an overview of the global Lenalidomide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Lenalidomide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Lenalidomide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Lenalidomide market size, projected growth trends, production technologies, key applications, and end-use industries.

Lenalidomide Segment by Company

Celgene

SL Pharma

Lenalidomide Segment by Type

5 mg Capsules

10 mg Capsules

15 mg Capsules

25 mg Capsules

Lenalidomide Segment by Application

Multiple myeloma (MM)

Myelodysplastic syndromes (MDS)

Lenalidomide Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Lenalidomide status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Lenalidomide market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Lenalidomide significant trends, drivers, influence factors in global and regions.

6. To analyze Lenalidomide competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lenalidomide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lenalidomide and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lenalidomide.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Lenalidomide market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Lenalidomide industry.

Chapter 3: Detailed analysis of Lenalidomide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Lenalidomide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Lenalidomide in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Lenalidomide Industry Trends Table 2. Lenalidomide Industry Drivers Table 3. Lenalidomide Industry Opportunities and Challenges Table 4. Lenalidomide Industry Restraints Table 5. Global Lenalidomide Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Lenalidomide Revenue Share by Company (2021-2026) Table 7. Global Lenalidomide Sales Volume by Company (K Pcs) & (2021-2026) Table 8. Global Lenalidomide Sales Volume Share by Company (2021-2026) Table 9. Global Lenalidomide Average Price (USD/Pcs) of Company (2021-2026) Table 10. Global Lenalidomide Company Ranking, (2024-2026) & (USD Million) Table 11. Global Lenalidomide Key Company Manufacturing Base & Headquarters Table 12. Global Lenalidomide Company, Product Type & Application Table 13. Global Lenalidomide Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Lenalidomide by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 5 mg Capsules Table 18. Significant Companies of 10 mg Capsules Table 19. Significant Companies of 15 mg Capsules Table 20. Significant Companies of 25 mg Capsules Table 21. Global Lenalidomide Sales Volume by Type 2021 VS 2025 VS 2032 (K Pcs) Table 22. Global Lenalidomide Sales Volume by Type (2021-2026) & (K Pcs) Table 23. Global Lenalidomide Sales Volume by Type (2027-2032) & (K Pcs) Table 24. Global Lenalidomide Sales Volume Share by Type (2021-2026) Table 25. Global Lenalidomide Sales Volume Share by Type (2027-2032) Table 26. Global Lenalidomide Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Lenalidomide Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Lenalidomide Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Lenalidomide Sales Value Share by Type (2021-2026) Table 30. Global Lenalidomide Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Multiple myeloma (MM) Table 32. Significant Companies of Myelodysplastic syndromes (MDS) Table 33. Global Lenalidomide Sales Volume by Application 2021 VS 2025 VS 2032 (K Pcs) Table 34. Global Lenalidomide Sales Volume by Application (2021-2026) & (K Pcs) Table 35. Global Lenalidomide Sales Volume by Application (2027-2032) & (K Pcs) Table 36. Global Lenalidomide Sales Volume Share by Application (2021-2026) Table 37. Global Lenalidomide Sales Volume Share by Application (2027-2032) Table 38. Global Lenalidomide Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Lenalidomide Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Lenalidomide Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Lenalidomide Sales Value Share by Application (2021-2026) Table 42. Global Lenalidomide Sales Value Share by Application (2027-2032) Table 43. Global Lenalidomide Sales by Region: 2021 VS 2025 VS 2032 (K Pcs) Table 44. Global Lenalidomide Sales by Region (2021-2026) & (K Pcs) Table 45. Global Lenalidomide Sales Market Share by Region (2021-2026) Table 46. Global Lenalidomide Sales by Region (2027-2032) & (K Pcs) Table 47. Global Lenalidomide Sales Market Share by Region (2027-2032) Table 48. Global Lenalidomide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Lenalidomide Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Lenalidomide Sales Value Share by Region (2021-2026) Table 51. Global Lenalidomide Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Lenalidomide Sales Value Share by Region (2027-2032) Table 53. Global Lenalidomide Market Average Price (USD/Pcs) by Region (2021-2026) Table 54. Global Lenalidomide Market Average Price (USD/Pcs) by Region (2027-2032) Table 55. Global Lenalidomide Sales by Country: 2021 VS 2025 VS 2032 (K Pcs) Table 56. Global Lenalidomide Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Lenalidomide Sales by Country (2021-2026) & (K Pcs) Table 58. Global Lenalidomide Sales Market Share by Country (2021-2026) Table 59. Global Lenalidomide Sales by Country (2027-2032) & (K Pcs) Table 60. Global Lenalidomide Sales Market Share by Country (2027-2032) Table 61. Global Lenalidomide Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Lenalidomide Sales Value Market Share by Country (2021-2026) Table 63. Global Lenalidomide Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Lenalidomide Sales Value Market Share by Country (2027-2032) Table 65. Celgene Company Information Table 66. Celgene Business Overview Table 67. Celgene Lenalidomide Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 68. Celgene Lenalidomide Product Portfolio Table 69. Celgene Recent Development Table 70. SL Pharma Company Information Table 71. SL Pharma Business Overview Table 72. SL Pharma Lenalidomide Sales (K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 73. SL Pharma Lenalidomide Product Portfolio Table 74. SL Pharma Recent Development Table 75. Key Raw Materials Table 76. Raw Materials Key Suppliers Table 77. Lenalidomide Distributors List Table 78. Lenalidomide Customers List Table 79. Research Programs/Design for This Report Table 80. Authors List of This Report Table 81. Secondary Sources Table 82. Primary Sources List of Figures Figure 1. Lenalidomide Product Image Figure 2. Global Lenalidomide Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lenalidomide Sales Value (2021-2032) & (US$ Million) Figure 4. Global Lenalidomide Sales (2021-2032) & (K Pcs) Figure 5. Global Lenalidomide Sales Average Price (USD/Pcs) & (2021-2032) Figure 6. Global Lenalidomide Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 5 mg Capsules Image Figure 10. 10 mg Capsules Image Figure 11. 15 mg Capsules Image Figure 12. 25 mg Capsules Image Figure 13. Global Lenalidomide Sales Volume by Type (2021 VS 2025 VS 2032) & (K Pcs) Figure 14. Global Lenalidomide Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Lenalidomide Sales Volume Share by Type (2021-2032) Figure 16. Global Lenalidomide Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Lenalidomide Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Lenalidomide Sales Value Share by Type (2021-2032) Figure 19. Multiple myeloma (MM) Image Figure 20. Myelodysplastic syndromes (MDS) Image Figure 21. Global Lenalidomide Sales Volume by Application (2021 VS 2025 VS 2032) & (K Pcs) Figure 22. Global Lenalidomide Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Lenalidomide Sales Volume Share by Application (2021-2032) Figure 24. Global Lenalidomide Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Lenalidomide Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Lenalidomide Sales Value Share by Application (2021-2032) Figure 27. Global Lenalidomide Sales by Region: 2021 VS 2025 VS 2032 (K Pcs) Figure 28. Global Lenalidomide Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Lenalidomide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Lenalidomide Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Lenalidomide Sales Value (2021-2032) & (US$ Million) Figure 32. North America Lenalidomide Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Lenalidomide Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Lenalidomide Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Lenalidomide Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Lenalidomide Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Lenalidomide Sales Value (2021-2032) & (US$ Million) Figure 38. South America Lenalidomide Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Lenalidomide Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Lenalidomide Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Lenalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Lenalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Lenalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Lenalidomide Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Lenalidomide Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 5 mg Capsules
  • 10 mg Capsules
  • 15 mg Capsules
  • 25 mg Capsules
Applications
  • Multiple myeloma (MM)
  • Myelodysplastic syndromes (MDS)
Companies covered
  • Celgene
  • SL Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Lenalidomide Sales Value (2021-2032)
  4. 1.2.2 Global Lenalidomide Sales Volume (2021-2032)
  5. 1.2.3 Global Lenalidomide Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Lenalidomide Market Dynamics
  1. 2.1 Lenalidomide Industry Trends
  2. 2.2 Lenalidomide Industry Drivers
  3. 2.3 Lenalidomide Industry Opportunities and Challenges
  4. 2.4 Lenalidomide Industry Restraints
3 Lenalidomide Market by Company
  1. 3.1 Global Lenalidomide Company Revenue Ranking in 2025
  2. 3.2 Global Lenalidomide Revenue by Company (2021-2026)
  3. 3.3 Global Lenalidomide Sales Volume by Company (2021-2026)
  4. 3.4 Global Lenalidomide Average Price by Company (2021-2026)
  5. 3.5 Global Lenalidomide Company Ranking (2024-2026)
  6. 3.6 Global Lenalidomide Company Manufacturing Base and Headquarters
  7. 3.7 Global Lenalidomide Company Product Type and Application
  8. 3.8 Global Lenalidomide Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Lenalidomide Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Lenalidomide Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Lenalidomide Market by Type
  1. 4.1 Lenalidomide Type Introduction
  2. 4.1.1 5 mg Capsules
  3. 4.1.2 10 mg Capsules
  4. 4.1.3 15 mg Capsules
  5. 4.1.4 25 mg Capsules
  6. 4.2 Global Lenalidomide Sales Volume by Type
  7. 4.2.1 Global Lenalidomide Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Lenalidomide Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Lenalidomide Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Lenalidomide Sales Value by Type
  11. 4.3.1 Global Lenalidomide Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Lenalidomide Sales Value by Type (2021-2032)
  13. 4.3.3 Global Lenalidomide Sales Value Share by Type (2021-2032)
5 Lenalidomide Market by Application
  1. 5.1 Lenalidomide Application Introduction
  2. 5.1.1 Multiple myeloma (MM)
  3. 5.1.2 Myelodysplastic syndromes (MDS)
  4. 5.2 Global Lenalidomide Sales Volume by Application
  5. 5.2.1 Global Lenalidomide Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Lenalidomide Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Lenalidomide Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Lenalidomide Sales Value by Application
  9. 5.3.1 Global Lenalidomide Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Lenalidomide Sales Value by Application (2021-2032)
  11. 5.3.3 Global Lenalidomide Sales Value Share by Application (2021-2032)
6 Lenalidomide Regional Sales and Value Analysis
  1. 6.1 Global Lenalidomide Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Lenalidomide Sales by Region (2021-2032)
  3. 6.2.1 Global Lenalidomide Sales by Region: 2021-2026
  4. 6.2.2 Global Lenalidomide Sales by Region (2027-2032)
  5. 6.3 Global Lenalidomide Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Lenalidomide Sales Value by Region (2021-2032)
  7. 6.4.1 Global Lenalidomide Sales Value by Region: 2021-2026
  8. 6.4.2 Global Lenalidomide Sales Value by Region (2027-2032)
  9. 6.5 Global Lenalidomide Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Lenalidomide Sales Value (2021-2032)
  12. 6.6.2 North America Lenalidomide Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Lenalidomide Sales Value (2021-2032)
  15. 6.7.2 Europe Lenalidomide Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Lenalidomide Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Lenalidomide Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Lenalidomide Sales Value (2021-2032)
  21. 6.9.2 South America Lenalidomide Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Lenalidomide Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Lenalidomide Sales Value Share by Country, 2025 VS 2032
7 Lenalidomide Country-level Sales and Value Analysis
  1. 7.1 Global Lenalidomide Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Lenalidomide Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Lenalidomide Sales by Country (2021-2032)
  4. 7.3.1 Global Lenalidomide Sales by Country (2021-2026)
  5. 7.3.2 Global Lenalidomide Sales by Country (2027-2032)
  6. 7.4 Global Lenalidomide Sales Value by Country (2021-2032)
  7. 7.4.1 Global Lenalidomide Sales Value by Country (2021-2026)
  8. 7.4.2 Global Lenalidomide Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Lenalidomide Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Lenalidomide Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Lenalidomide Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Lenalidomide Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Lenalidomide Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Lenalidomide Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Lenalidomide Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Lenalidomide Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Lenalidomide Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Lenalidomide Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Lenalidomide Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Lenalidomide Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Lenalidomide Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Lenalidomide Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Lenalidomide Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Lenalidomide Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Lenalidomide Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Lenalidomide Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Lenalidomide Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Lenalidomide Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Lenalidomide Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Lenalidomide Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Lenalidomide Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Lenalidomide Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Lenalidomide Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Lenalidomide Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Lenalidomide Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Lenalidomide Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Lenalidomide Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Lenalidomide Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Lenalidomide Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Lenalidomide Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Lenalidomide Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Lenalidomide Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Lenalidomide Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Lenalidomide Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Lenalidomide Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Lenalidomide Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Lenalidomide Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Lenalidomide Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Lenalidomide Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Lenalidomide Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Lenalidomide Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Lenalidomide Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Lenalidomide Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Lenalidomide Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Lenalidomide Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Lenalidomide Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Lenalidomide Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Lenalidomide Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Lenalidomide Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Lenalidomide Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Lenalidomide Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Lenalidomide Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Lenalidomide Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Lenalidomide Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Lenalidomide Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Lenalidomide Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Lenalidomide Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Lenalidomide Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Lenalidomide Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Lenalidomide Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Lenalidomide Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Lenalidomide Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Lenalidomide Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Lenalidomide Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Lenalidomide Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Lenalidomide Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Lenalidomide Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Lenalidomide Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Lenalidomide Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Lenalidomide Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Lenalidomide Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Lenalidomide Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Lenalidomide Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Lenalidomide Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Lenalidomide Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Lenalidomide Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Lenalidomide Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Lenalidomide Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Lenalidomide Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Lenalidomide Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Lenalidomide Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Lenalidomide Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Celgene
  2. 8.1.1 Celgene Company Information
  3. 8.1.2 Celgene Business Overview
  4. 8.1.3 Celgene Lenalidomide Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Celgene Lenalidomide Product Portfolio
  6. 8.1.5 Celgene Recent Developments
  7. 8.2 SL Pharma
  8. 8.2.1 SL Pharma Company Information
  9. 8.2.2 SL Pharma Business Overview
  10. 8.2.3 SL Pharma Lenalidomide Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 SL Pharma Lenalidomide Product Portfolio
  12. 8.2.5 SL Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Lenalidomide Value Chain Analysis
  2. 9.1.1 Lenalidomide Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Lenalidomide Sales Mode & Process
  6. 9.2 Lenalidomide Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Lenalidomide Distributors
  9. 9.2.3 Lenalidomide Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst